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OBJECTIVES: Eosinophilic esophagitis (EoE), a chronic food allergic disease, lacks sensitive and specific peripheral
biomarkers. We hypothesized that levels of EoE-related biomarkers captured using a 1-hour minimally
invasive Esophageal String Test (EST) would correlate with mucosal eosinophil counts and tissue
concentrations of these same biomarkers. We aimed to determine whether a 1-hour EST accurately
distinguishes active from inactive EoE or a normal esophagus.
METHODS: In a prospective, multisite study, children and adults (ages 7–55 years) undergoing a clinically
indicated esophagogastroduodenoscopy performed an EST with an esophageal dwell time of 1 hour.
Subjects were divided into 3 groups: active EoE, inactive EoE, and normal esophageal mucosa.
Eosinophil-associated protein levels were compared between EST effluents and esophageal biopsy
extracts. Statistical modeling was performed to select biomarkers that best correlated with and
predicted eosinophilic inflammation.
RESULTS: One hundred thirty-four subjects (74 children, 60 adults) with active EoE (n 5 62), inactive EoE
(n5 37), and patient controls with a normal esophagus (n5 35) completed the study. EST-captured
eosinophil-associated biomarkers correlated significantly with peak eosinophils/high-power field,
endoscopic visual scoring, and the same proteins extracted from mucosal biopsies. Statistical
modeling, using combined eotaxin-3 andmajor basic protein-1 concentrations, led to the development
of EoE scores that distinguished subjects with active EoE from inactive EoE or normal esophagi. Eighty-
seven percent of children, 95% of parents, and 92% of adults preferred the EST over endoscopy if it
provided similar information.
DISCUSSION: The 1-hour EST accurately distinguishes active from inactive EoE in children and adults and may
facilitate monitoring of disease activity in a safe and minimally invasive fashion.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/B281
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Eosinophilic esophagitis (EoE) is a chronic immune-mediated
food-allergic inflammatory disease affecting children and adults
worldwide (1). An increasing number of studies have identified
mucosal inflammatory patterns, novel therapeutic targets, and
the natural history of the disease (2–4). Left untreated, active EoE
seems to lead to esophageal fibrosis as the duration of diagnos-
tic delay, based on symptom history, predicts the presence of
stricture (2); treatment that reduces inflammation may limit
complications (4,5). Thus, monitoring eosinophilic esophageal
inflammation is critical to guide treatment decisions and permit
forecasting of long-term patient outcomes.
Quantification of mucosal eosinophilia provides a meaningful
metric to assess inflammation, but endoscopic procurement of
mucosal samples has been hampered by the need for anesthesia/
sedation, potential complications, high costs, time away from work
and school, and limited assessment of the full esophageal mucosal
surface. To address these concerns, a number of studies have sought
to identify laboratory, functional, or radiographic biomarkers to
replacemucosal eosinophilia as a diagnostic andmonitoringmetric.
Ourworkandothershave shown that eosinophil-associatedproteins
(EAPs) from the esophageal lumen correlate with EoE disease ac-
tivity (6–9). We showed in children that eosinophil-derived granule
proteins (EDGPs) captured in a 16-hour dwell time by the Esoph-
ageal String Test (EST) (16-hour EST) significantly correlated with
the same biomarkers in endoscopically obtained mucosal biopsy
samples (6). Notably, the 16-hour EST discriminated between chil-
dren with active EoE from those with treated EoE in remission,
gastroesophageal reflux disease (GERD), and a normal esophagus
(6). Here we sought to determine whether the EST could capture
EAPs in a clinically practical timeframe of 1 hour in children and
adults, and whether these proteins correlated with EoE disease ac-
tivity. EAPs included EDGPs as well as 2 eosinophil chemokines,
eotaxin-2 (Eot2) and eotaxin-3 (Eot3).
METHODS
Subject recruitment
This prospective study was conducted at Children’s Hospital
Colorado, Ann & Robert H. Lurie Children’s Hospital of Chi-
cago, Northwestern University Hospital and Medical Center,
University of Colorado Hospital, and Riley Children’s Hospital.
Subjects were recruited if they were (i) between the ages of 7–55
and (ii) undergoing a clinically indicated upper endoscopy with
biopsy for symptoms of abdominal pain, vomiting, growth
failure, dysphagia, or a history of EoE. Exclusion criteria in-
cluded a history of esophageal stenosis defined as ,10 mm di-
ameter, gelatin allergy, or other factors placing subjects at
increased risk of endoscopic complications (bleeding diatheses
and connective tissue diseases). After review of the medical
record, subject diagnoses were confirmed according to the fol-
lowing criterion: (i) EoE-active—symptoms of esophageal dys-
function, esophageal eosinophilia$15 eosinophils/high-power
field (HPF), in whom other causes of symptoms and esophageal
eosinophilia were excluded as per consensus recommendations
(10,11); (ii) EoE-inactive—EoE as defined above but lack of
symptoms and esophageal eosinophilia ,15 eosinophils/HPF,
after at least 8 weeks of EoE treatment (topical steroids, dietary
elimination, elemental diet) and (iii) patient controls with
normal esophagus—symptoms leading to endoscopic testing
and normal mucosal appearance and histology of the upper
gastrointestinal tract assessed. All enrolled subjects with EoE
had failed treatment with proton pump inhibitors. The study
was approved by the Institutional Review Boards (IRBs) of
University of Colorado School of Medicine and Children’s
Hospital of Colorado (Colorado Multi-institutional IRB), Uni-
versity of Illinois at Chicago, Ann & Robert H. Lurie Children’s
Hospital, Northwestern University, and Indiana University and
is listed at clinicaltrials.gov as protocol NCT02008903.
EST performance and histological assessment
The Enterotest string device (HDC Corporation, Milpitas, CA) was
used to capture esophageal contents (12–17). The device consists of
a weighted gelatin capsule containing 90 cm of nylon string. The
capsule was swallowed no more than 4 hours before the scheduled
endoscopic procedure, and the proximal end of the string was taped
to the subject’s cheek. One hour after swallowing the capsule, the
string was removed, the esophageal segment was harvested and
placed in EST elution buffer, and the eluate was frozen for EAP
analyses as described previously (6). Subjects then underwent en-
doscopy with biopsy while pinch biopsies were obtained from
proximal and distal esophageal mucosal surfaces and snap frozen.
Both string and biopsies were stored at280 °C until processed and
batch analyzed at a later time. Diagnostic biopsies were placed in
neutral buffered formalin for pathology processing, hematoxylin and
eosin staining, and eosinophil enumeration as previously described;
results were reported as peak eosinophils/HPF (eos/HPF) (surface
area 5 0.26 mm2) (6). To determine subject satisfaction with the
1-hour EST, study participants were asked to complete a survey. For
pediatric subjects, bothchildrenandparentswere asked toparticipate
in the survey, and for adult subjects, only the participant responded.
Mucosal appearance assessment
An EoE Endoscopic Reference Score (EREFS) was recorded for
each subject. Scores noted and graded the presence of the following
esophageal features: edema, rings, exudates, furrows, and stricture.
Assessmentsweremade in real timeor retrospectivelyusing images
taken during endoscopy as previously described (18).
EST and mucosal biopsy processing and analysis
EST samples and mucosal biopsies were processed for EAP
quantification as previously described (6). EAP concentrations in
biopsy extracts were normalized based on extracted protein
concentration and reported as ng biomarker/mg protein. EAP
concentrations in EST samples are reported as ng/mL of EST
supernatant. For the purposes of this study, EAPs were proteins
associated with eosinophils and EoE. Measured EAPs included
the EDGPs eosinophil-derived neurotoxin (EDN), eosinophil
peroxidase (EPX), and major basic protein 1 (MBP-1), the eo-
sinophil cytosolic protein Charcot-Leyden crystal protein/
Galectin-10 (CLC/Gal-10), Eot2, and Eot3. ELISA was per-
formed on biopsy extracts and EST samples using either com-
mercially available or in-house tests as follows: EDN (MBL
International, Woburn, MA), EPX (Lee Laboratory assay,
Scottsdale, AZ), MBP-1, CLC/Gal-10, (Ackerman Laboratory
assay, Chicago, IL), Eot2 (Quantikine; R&D Systems, Minneap-
olis,MN), and Eot3 (DuoSet, R&DSystems,Minneapolis,MN) as
previously described (6,19).
Statistical analysis
SAS9.4 (SAS Institute, Cary,NC) andR (RFoundation for Statistical
Computing, Vienna, Austria. URL https://www.R-project.org/) (20)
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software were used for analysis. Continuous data were summa-
rized using mean plus SD or median plus interquartile or range.
Parametric and nonparametric one-way Analysis of Variance
(ANOVA), as appropriate, andx2 test for associationwere used to
compare 3 groups of subjects (i.e., EoE active, EoE inactive, and
normal) with respect to continuous and categorical variables.
Pearson or Spearman correlation coefficients, as appropriate,
were used to examine the correlation of biomarkers with other
continuous variables. Receiver operating characteristic (ROC)
analysis using the SAS logistic regression procedure was used to
examine the discriminating ability of biomarker(s) to differenti-
ate active EoE ($15 eos/HPF) from inactive EoE (,15 eos/HPF)
in subjects with diagnosed EoE, and to differentiate subjects with
active EoE from those with inactive EoE or patient controls with
a normal esophagus. The integrated discrimination improvement
(IDI) index (21) was analyzed using the SAS macro by Kennedy
and Pencina (22). An EoE score was developed based on the
predicted probability of having active EoE ($15 eos/HPF) using
a logistic regression model with logit link; a nomogram for this
algorithm was generated using the R package, “rms”.
RESULTS
Subject characterization
One hundred thirty-four (134) subjects (74 children, 60 adults)
completed the study from participating sites (Children’s Hospital
Colorado, n5 52; LurieChildren’sHospital, n5 23;Northwestern
University Hospital, n 5 49; Riley Children’s Hospital, n 5 2;
University of Colorado Hospital, n5 8). Demographics and clin-
ical features are shown in Table 1. Patients were treated with
topical steroids, elimination diet, or both steroids and diet. No
serious adverse events were recorded and side effects noted
during the EST included gagging (n 5 30), nausea (n 5 5), and
sore throat (n5 6). Because of gagging, 14%of consented patients
were not able to complete the study; no subjects required medi-
cations for gagging.
EAP levels from biopsy and EST samples correlate with mucosal
eosinophil counts
We first sought to determine whether EAPs measured in samples
from mucosal biopsies and the 1-hour EST correlated with peak
eosinophil density in mucosal samples. As shown in Figure 1, all
EAPs from mucosal biopsy sample extracts correlated signifi-
cantly with mucosal eosinophil counts, ranging from r5 0.61 for
Eot3 to 0.40 for Eot2 (all P, 0.0001). Similarly, there was a sig-
nificant correlation of all EAPs from 1-hour EST string samples
with mucosal eosinophil counts, ranging from r5 0.70 and 0.68
for CLC/Gal-10 and Eot3, respectively, to r5 0.53 for Eot2) (all
P , 0.0001). Consistent with our previous study, our results
indicate that both mucosal (biopsy) and luminal (EST) concen-
trations of EAPs can serve as surrogate markers of peak intra-
epithelial eosinophil counts, the present gold standard for
assessing esophageal inflammation in EoE.
EAP levels from EST samples correlate with those in
biopsy samples
Because EAPs captured by the EST were strongly associated
with esophageal eosinophilia, we next determined whether
EAPs captured by the 1-hour EST correlated with the same EAPs
extracted and quantified from esophageal biopsies. All EAP
concentrations measured in samples obtained from the 1-hour
EST and mucosal biopsies were found to significantly correlate
with one another (Figure 2), these correlations being greatest for
Eot3 (r5 0.73), followed by Eot2 (r5 0.60), EPX (r5 0.49), and
MBP-1 (r 5 0.46) (all P , 0.0001).
Endoscopic appearance of EoE correlates with EST and biopsy
EAP levels
Previous studies revealed that EREFS scores correlate with mu-
cosal eosinophilia in adult and pediatric patients with EoE (18).
We determined whether this visual analog of EoE disease activity
correlated with eos/HPF and EAP concentrations in 1-hour
EST and biopsy samples. Consistent with previous reports,
pediatric and adult EREFS from subjects with active EoE, in-
active EoE, and controls with a normal esophagus correlated
significantly with eos/HPF in proximal, distal, and total
esophagus (rs from 0.31 to 0.74) (see Table S1A, Supplementary







Mean age yr (SD) 24.9 (13.8) 29.3 (17.1) 17.1 (9.7)
Sex (F/M) 13/49 21/16 22/13
Race
White/Caucasian 81% 84% 71%
Hispanics 6% 8% 20%
Asian 2% 3% 0%
Black/African American 3% 0% 3%
Native American 0% 0% 3%
Other 8% 5% 3%
Most common symptomsa
Dysphagia 87% 86% 80%
Abdominal pain 35% 35% 60%
Heartburn 32% 27% 57%
Coughing 32% 27% 46%





Asthma 39% 51% 34%
Eczema 32% 30% 11%
EREFS scoresb
Distal (SD) 3.80 (2.05) 1.48 (1.12) 0.75 (1.76)
Proximal (SD) 3.02 (2.03) 1.12 (1.05) 0.75 (1.54)
Totalc (SD) 6.82 (3.87) 2.61 (1.85) 1.50 (3.29)
Peak Eos/HPF (SD) 52.61 (30.89) 2.95 (4.65) 0.00 (0.00)
eos/HPF, eosinophils/high-power field; EREFS, Eosinophilic Esophagitis
Endoscopic Reference Score; EoE, eosinophilic esophagitis.
aSubjects had more than one symptom or allergy.
bEREFS scores or endoscopic images to generate EREFS were available for the
following number of subjects: EoE active, n550; EoE inactive, n5 33; normal,
n 5 12.
cSum of proximal 1 distal EREFS scores, indicating total esophageal
involvement.










Digital Content 1, http://links.lww.com/AJG/B281). Notably,
EREFS also correlated significantly with both EST and mucosal
biopsy concentrations of all EAPs measured (rs from 0.31 to 0.680
(see Table S1B, Supplementary Digital Content 1, http://links.lww.
com/AJG/B281); no differences were observed between pediatric
and adult subjects in analyzing these data (not shown).
Figure 1. Eosinophil-associated biomarkers in EST and biopsy extract samples correlate with peak histologic eosinophil counts. Spearman analyses
correlating ESTsamples (left panel) andbiopsy extracts (right panel) with peak eosinophils/HPFwere performed. Spearman rank correlation coefficients (r)
and associated P-values are shown. Symbols denote subjects with (d) EoE, active; (◯) EoE, inactive; (à) normal esophagus. CLC/GAL-10, Charcot-Leyden
crystal protein/Galectin-10; EDN, eosinophil-derived neurotoxin; EoE, eosinophilic esophagitis; eos/HPF, eosinophils/high-power field; Eot2, eotaxin 2;
Eot3, eotaxin 3; EPX, eosinophil peroxidase; EST, esophageal string test; MBP-1, eosinophil granule major basic protein 1.
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EAPs captured by the EST distinguish active from inactive EoE,
and from normal esophagus.
Because EAPs collected with the 1-hour EST correlated with
mucosal eosinophilia, EAP levels in mucosal biopsies, and the
endoscopic appearance of the esophageal mucosa, we next de-
termined whether EAP levels from the EST were associated with
disease activity. As shown in Figure 3, EAP concentrations obtained
from EST samples were significantly higher in the active EoE group
Figure 2. Eosinophil-associated biomarkers captured by the EST are significantly correlated with those measured in esophageal mucosal biopsies.
Spearman rank correlation coefficients (r) and associated P-values are shown. Symbols denote subjects with (d) EoE, active; (◯) EoE, inactive; (à) normal
esophagus. CLC/GAL-10, Charcot-Leyden crystal protein/Galectin-10; EDN, eosinophil-derived neurotoxin; EoE, eosinophilic esophagitis; Eot2, eotaxin 2;
Eot3, eotaxin 3; EPX, eosinophil peroxidase; EST, esophageal string test; MBP-1, eosinophil granule major basic protein 1.










compared to inactive EoE and normal groups (see Table S2, Sup-
plementary Digital Content 1, http://links.lww.com/AJG/B281). To
determine whether 1-hour EST-based biomarker measurements
have utility for monitoring esophageal inflammation, we
generated ROC curves for the 1-hour EST-obtained individual
EAPs. Consistent with our previous study (6), ROC analyses of
the 1-hour EST individual EAPs showed considerable sensitivity
and specificity for distinguishing between active EoE, inactive
Figure 3. Luminal concentrations of eosinophil-associated biomarkers measured in EST samples differentiate subjects with active EoE, inactive EoE, or
normal esophagus. Biomarkers were measured by ELISA in EST and mucosal biopsy samples. Levels in biopsy extracts were normalized to total protein
content and are reported as ng biomarker/mg total protein. Biomarker levels in EST samples are reported as ng/mL of EST supernatant. Results are
presented asbox/whisker plotswhere thehorizontal line anddiamond inside thebox aremedianandmeanvalues, respectively; thebox is the interquantiles;
the lower and upper ends of whiskers are 5th and 95th percentiles, respectively; and symbols are data points with extreme values. Differences in protein
biomarker levels across patient groups were compared using nonparametric ANOVA (refer to Supplemental Table S1 for P-values, see Supplementary
Digital Content 1, http://links.lww.com/AJG/B281). CLC, Charcot-Leyden crystal protein; EoE, eosinophilic esophagitis; EDN, eosinophil-derived neuro-
toxin; Eot2, eotaxin 2; Eot3, eotaxin 3; EPX, eosinophil peroxidase; EST, esophageal string test; MBP-1, eosinophil granule major basic protein 1.
Figure4.ROCcurves show significant sensitivity and specificity for identifying active EoE ($15Eos/hpf) among all patients (active or inactive EoE, or normal
esophagus). ROC analyses used the level of Eot3 plus one additional biomarker as indicated captured by the 1-hour ESTor measured in mucosal biopsy
extracts (lower right panel; see Figure S2, Supplementary Digital Content 1, http://links.lww.com/AJG/B281). Results are shown for Eot3, Eot3 plus CLC
(Gal-10), Charcot-Leyden crystal protein/Galectin-10;MBP-1, EDN, eosinophil-derived neurotoxin; EPX, eosinophil peroxidase; andEot2, eotaxin 2. Points
on theROCcurves are labeledby their predictive probabilities. TheAUC is indicated above eachpanel; AUC values.0.80 are consideredhighly predictive.
The table (lower right panel) shows the comparative AUC values for the 1-hour EST vs mucosal biopsy extracts for the indicated biomarker combinations.
AUC, area under the curve; CLC, Charcot-Leyden crystal protein; EoE, eosinophilic esophagitis; EDN, eosinophil-derived neurotoxin; Eot2, eotaxin 2; Eot3,
eotaxin 3; EPX, eosinophil peroxidase; MBP-1, eosinophil granule major basic protein 1; ROC, receiver operating characteristic.
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EoE, and a normal esophagus (see Figure S1, Supplementary
Digital Content 1, http://links.lww.com/AJG/B281), with area
under the curve (AUC) values for EST samples between 0.84 and
0.70 for Eot3 and Eot2, respectively, comparable to AUC values
for biopsy extracts ranging from 0.85 for Eot3 to 0.76 for Eot2;
AUC values .0.80 are considered highly predictive. Thus, the
levels of Eot3measured in both EST samples and biopsy extracts
showed the greatest sensitivity and specificity for distinguishing
patients with active EoE from those with inactive EoE or
a normal esophagus.
To further maximize the discriminating ability of these bio-
marker analytes to distinguish active EoE among these subject
groups, we performed additional ROC analyses using combined
sets of Eot3 plus each of the EDGPs in the EST samples as shown
in Figure 4. The combination of Eot3 with MBP-1 in this model,
for distinguishing active EoE from inactive EoE and normal pa-
tient controls (AUC 5 0.86 and 0.90 for EST and biopsy, re-
spectively), improved the average sensitivity (true positives) by
0.039 (0.693 vs 0.652) and also improved the average 1-specific
(false positive rate) by 0.014 (0.261 vs 0.275), resulting in an IDI of
0.053 (see Tables S3 and S4, Supplementary Digital Content 1,
http://links.lww.com/AJG/B281); the IDI, a summary of the
change in detection rate and false positive rate (i.e., 1-specificity),
is shown graphically in Figure S4 (see Figure S4 Supplementary
Digital Content 1, http://links.lww.com/AJG/B281) (23). Similar
ROC analyses using combined sets of Eot3 plus each of the in-
dividual EDGPs in biopsy extracts are shown in Figure S2 (see
Supplementary Digital Content 1, http://links.lww.com/AJG/
B281). Outcome measures for the EST (string) compared to bi-
opsies (extracts) for the two-biomarker model for subjects with
active EoE, inactive EoE, or normal esophagus are shown in
Table 2 for the combination of Eot3 with each of the EDGPs
studied; these combinations showed highly significant and
comparable outcome measures including probability, sensitivity,
specificity, positive predictive value (PPV), negative predictive
value (NPV), and area under the curve (AUC), further supporting
use of the EST for capturing active esophageal eosinophilic in-
flammation among all study patients performing the EST.
We next performed similar ROC analyses for the ability of
Eot3 1 MBP-1 combined in this model to improve the proba-
bility of discriminating between subjects with active vs inactive
(treated) EoE in subjects with a confirmed diagnosis of EoE
(Figure 5). Combined, Eot31MBP-1 significantly improved the
average sensitivity (true positives) by 0.046 (0.766 vs 0.72) and
also improved 1-specific (false positive rate) by 0.032 (0.438 vs
0.471), leading to an IDI value of 0.078 (see Tables S3 and S4,
Supplementary Digital Content 1, http://links.lww.com/AJG/
B281). Combining levels of CLC/Gal-10 or EPX with Eot3 sim-
ilarly improved false positive rates, but had smaller influences on
sensitivity, with smaller IDI values for CLC/Gal-10 and EPX
compared to MBP-1 (see Table S3, Supplementary Digital Con-
tent 1, http://links.lww.com/AJG/B281). Similar ROC analyses
using combined sets of Eot3 plus the EDGPs in biopsy extracts are
shown in Figure S3(see Figure S3, SupplementaryDigital Content
Table 2. Outcomemeasures for the EST (string) compared to biopsy for the 2 biomarkermodela for all subjectsb (active EoEc, inactive EoEd,
and normal esophagus)






String 0.46833 0.72 0.89 0.86 0.76 0.86
Biopsy 0.52499 0.76 0.93 0.92 0.79 0.90
Eotaxin 2
String 0.36657 0.79 0.83 0.81 0.81 0.84
Biopsy 0.42234 0.74 0.94 0.92 0.78 0.85
EDN
String 0.30753 0.87 0.71 0.73 0.85 0.86
Biopsy 0.40143 0.82 0.90 0.89 0.84 0.92
CLC/Gal-10
String 0.31295 0.87 0.77 0.78 0.86 0.89
Biopsy 0.37238 0.85 0.87 0.87 0.86 0.92
EPX
String 0.38848 0.77 0.85 0.82 0.80 0.85
Biopsy 0.36933 0.79 0.90 0.89 0.81 0.87
CLC/GAL-10, Charcot-Leyden crystal protein/Galectin-10; EDN, eosinophil-derived neurotoxin; EoE, eosinophilic esophagitis; Eot2, eotaxin 2; Eot3, eotaxin 3; EPX,
eosinophil peroxidase; EST, esophageal string test; MBP-1, eosinophil granule major basic protein 1; ROC, receiver operating characteristic.
aThe “best” cutoff by Youden’s J criteria for the model with 2 predictors (Model 2).
bNumber of eligible subjects in analysis: active EoE (62), inactive EoE (37), and normal (35).
cPeak eos $ 15/HPF.
dPeak eos , 15/HPF.
eROC, area under curve (c-statistic).










1, http://links.lww.com/AJG/B281). Outcome measures for ESTs
(string) compared to biopsies (extracts) for the two-biomarker
(Eot31 EDGP) model for distinguishing subjects with active vs
inactive EoE among all subjectswith a confirmeddiagnosis of EoE
are shown in Table 3; these combinations similarly showed highly
significant and comparable outcome measures for probability,
sensitivity, specificity, PPV, NPV, and AUC for EST vs biopsy
samples, further demonstrating utility of the 1-hour EST for
distinguishing active from inactive esophageal inflammation
among study patients with an EoE diagnosis. Overall, the com-
bined biomarker model (model 2) using Eot31 MBP-1 showed
the greatest ability to assess mucosal eosinophilic inflammation,
being optimal for differentiating active EoE from normal
esophagus, and for discriminating between EoE subjects with
active vs inactive disease.
With the finding that measuring a combination of Eot3 and
the EDGPs (particularly MBP-1) permits detection of mucosal
inflammation in subjects with EoE, we used statistical modeling
to provide a means of translating these biomarkers into the
probability of having a threshold number of esophageal eosino-
phils. This model utilizes a combination of the concentrations of
Eot3 and MBP-1 from a 1-hour EST sample to generate the
probability of a subject having mucosal eosinophilia $15
eosinophils/HPF. The nomogram in Figure S5 (see Figure S5,
Supplementary Digital Content 1, http://links.lww.com/AJG/
B281) was generated using Eot3 andMBP-1 levels captured by 1-
hour ESTs from all patients with a confirmed diagnosis of EoE for
the purpose of discriminating between subjects with active EoE
($15 peak eos/HPF) and those with inactive disease (,15 eos/
HPF), i.e., treated EoE subjects in remission. It provides the
probability of a subject with a known diagnosis of EoE being in
remission or continuing to have active esophageal inflammation
during treatment, e.g., following a food elimination diet or during
food reintroductions.
Subjects prefer the EST over traditional endoscopy
Of the 134 subjects completing the study, 44% completed a fol-
low-up survey. Of those responding, 98% of children and 96%
of parents were willing to repeat the EST, and 74% and 78% of
children and parents respectively preferred the 1-hour EST over
endoscopy if the child was to need another evaluation (Table 4).
Finally, 87%of children and 95%of parents indicated a preference
for performing an EST over endoscopy if it could provide similar
information. Of adult respondents who completed the EST, 92%
were willing to repeat the test, and of these, 75%preferred the EST
over endoscopy if another evaluation was needed. Finally, 92% of
adults indicated a preference for performing an EST over en-
doscopy if it could provide similar information.
DISCUSSION
Accumulated clinical experience and natural history studies have
documented the widespread and chronic nature of EoE (2).
Untreated EoE may lead to the development of esophageal
strictures, whereas treatment may prevent food impaction
Figure 5. ROC curves distinguish subjects with active EoE ($15 Eos/hpf) from inactive EoE (,15 Eos/hpf). ROC analyses used the level of Eot3 plus one
additional biomarker capturedby the1-hourESTormeasured inmucosal biopsyextracts (lower right panel; seeFigure S3, SupplementaryDigital Content 1,
http://links.lww.com/AJG/B281). Results are shown for Eot3, Eot3 plus CLC (Gal-10), Charcot-Leyden crystal protein/galectin-10; MBP-1, major basic
protein-1; EPX, eosinophil peroxidase; EDN, eosinophil-derived neurotoxin; and Eot2, eotaxin 2. Points on the ROC curves are labeled by their predictive
probabilities. The AUC is indicated above each panel; AUC values.0.80 are considered highly predictive. The table (lower right panel) shows the
comparative AUC values for the 1-hour EST vsmucosal biopsy extracts for the indicated biomarker combinations. AUC, area under the curve; CLC/GAL-10,
Charcot-Leyden crystal protein/Galectin-10; EoE, eosinophilic esophagitis; EDN, eosinophil-derived neurotoxin; Eot2, eotaxin 2; Eot3, eotaxin 3; EPX,
eosinophil peroxidase; MBP-1, eosinophil granule major basic protein 1; ROC, receiver operating characteristic.
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(24,25). Thus, assessment of esophageal inflammation has be-
come important for optimizing clinical outcomes for children
and adults with EoE. Since the present standard approach for
measuring inflammation relies on sedated endoscopy and biopsy,
development of alternatives to this approach are imperative.
Here, we demonstrate that the EST can capture biomarkers rel-
evant to EoE in a clinically useful time frame of 1 hour.
Biomarker measurements in fluids surrounding diseased
organs have been used to assess inflammation in a number of
diseases. For instance, tears, bronchial washes, and stool effluent
can provide valuable information in allergic conjunctivitis,
asthma, and inflammatory bowel diseases (26,27). Currently,
monitoring esophageal inflammation in EoE patients necessitates
sedated endoscopy with biopsy and histologic assessment of
esophageal eosinophilia. To limit costs, maximize data capture,
eliminate endoscopic and anesthetic complications, and save
time, we hypothesized that the minimally invasive EST could
capture EAPs in a convenient time frame of 1 hour, and EAP
concentrations would reflect that found in the tissue.
We previously reported the ability of the 16-hour EST to
successfully capture esophageal EAPs in an overnight sampling
period, and that the EDGPconcentrations significantly correlated
with those measured in mucosal biopsies (6). Here, we extend
thesefindings to capture samples in a shorter time frame of 1 hour
and to include EoE relevant cytokine analyses. In this regard,
pairing of the EST-derived concentrations of eosinophil granule
MBP-1, with Eot3/CCL26, led to a significant correlation with
mucosal biopsy-derived levels of those same proteins as well as
eosinophil counts. Similar to our previous study in children (6),
these results support the use of the EST to monitor inflammation
in both children and adults with EoE, and provide support for its
use in a clinically relevant time frame of 1 hour.
Our results support not only the EST’s ability to capture
mucosal inflammation but also in its ability to reflect gross evi-
dence of surface inflammation. Comparison of EST-captured
biomarkers to a pediatric- and adult-validated endoscopic EoE
reference score (EREFS) (18) identified significant correlations of
proximal, distal, and total EREFS with the levels of EST-captured
EAPs, including Eot2 and Eot3, which showed the greatest cor-
relations to total EREFS scores. Thesefindings further validate the
EST as a correlate for endoscopic assessment of disease activity in
pediatric and adult patients with EoE.
Since symptoms do not always correlate with mucosal in-
flammation, andperipheral biomarkers of EoE such as blood (28),
stool (29), urine (30), nasopharynx (31,32), or breath condensate
(33) have not attained sufficient sensitivity and specificity to be
clinically useful for determining the status of EoE disease activity,
the clinical impact of the EST is broad and significant. The EST
could be used in office-based settings, research studies, or clinical
trials to monitor inflammation following institution of new
therapy or changes in diet treatments. Current practice patterns
and research studies rely on sedated endoscopy and mucosal bi-
opsy after a change in treatment; in some cases, this can result in
multiple endoscopies over the course of a year. Use of the EST
would eliminate these repeat endoscopic studies, thus saving
money, time, and reducing potential complications. In clinical
practice, EoE patients may experience unexplained symptoms
that may be related to inflammation; in these circumstances,
Table 3. Outcomemeasures for the EST (string) compared to biopsy for the 2 biomarker modela for all subjects with EoEb (active EoEc and
inactive EoEd)
Predictors: Eot3 1 Probability level Sensitivity Specificity Positive predicative value Negative predicative value ROC AUCe
MBP1
String 0.78489 0.58 1.00 1.00 0.56 0.83
Biopsy 0.61165 0.76 0.88 0.92 0.65 0.86
Eotaxin 2
String 0.51348 0.74 0.80 0.87 0.64 0.80
Biopsy 0.56380 0.73 0.91 0.94 0.64 0.85
EDN
String 0.80754 0.52 0.97 0.97 0.54 0.81
Biopsy 0.83656 0.68 1.00 1.00 0.62 0.90
CLC/Gal-10
String 0.49998 0.77 0.77 0.85 0.66 0.84
Biopsy 0.47812 0.85 0.85 0.91 0.76 0.89
EPX
String 0.50981 0.77 0.80 0.87 0.67 0.82
Biopsy 0.50407 0.79 0.85 0.91 0.68 0.83
CLC/GAL-10, Charcot-Leyden crystal protein/Galectin-10; EDN, eosinophil-derived neurotoxin; EoE, eosinophilic esophagitis; Eot2, eotaxin 2; Eot3, eotaxin 3; EPX,
eosinophil peroxidase; EST, esophageal string test; MBP-1, eosinophil granule major basic protein 1; ROC, receiver operating characteristic.
aThe “best” cutoff by Youden’s J criteria for the model with 2 predictors (model 2).
bNumber of eligible subjects in analysis: active EoE (62) and inactive EoE (37).
cPeak eos $ 15/hpf.
dPeak eos , 15/hpf.
eROC, area under curve (c-statistic).










instead of endoscopy, the EST could be used to assess for the
presence (or absence) of inflammation that would then dictate
further diagnostics or treatment changes. The EST could also be
used for screening for occult inflammation in individuals at higher
risk or suspicion of EoE. For example, siblings or family members
of patients affected by EoE with subtle symptoms or highly allergic
patients considering oral immunotherapy could be tested with the
EST, because oral immunotherapy has been linked to the de-
velopment or unmasking of EoE in some individuals (34). Results
of these tests may lead to, or eliminate the need for, further testing.
Future studies will identify novel EoE-related biomarkers that
may predict various EoE phenotypes, such as those prone to food
impactions or stricturing, or therapeutic responsiveness to topical
steroids, diet, or future treatment with biologics (35). Finally, the
1-hour EST-based measurements of pathophysiologically relevant
biomarkers (3), such as those related to the esophagealmicrobiome
(36,37), epithelial barrier function (38,39), esophageal motility
(40,41), andmucosal remodeling (42,43)may provide insights into
novel therapeutic targets or personalized medicine approaches.
With respect to these proposed uses, studies to date support the
present clinical use of the EST tomonitor inflammation in patients
withEoE, especially sincemost children/parents, and adult patients
preferred the option of performing the 1-hour EST over un-
dergoing additional endoscopies with biopsy.
Other novel methods to assess the esophageal mucosa in
patients with EoE include transnasal endoscopy (44), the Cyto-
sponge (7,8,45), and tethered confocal microscopy (46,47).
Transnasal endoscopy requires an endoscopic device, specialized
training, provides a small sample size, and requires consultation
with a pathologist. The Cytosponge may be more challenging to
swallow and retrieve in children (7,8,45). Tethered microscopy
requires specialized equipment. In contrast to mucosal biopsy, the
EST is able to capture biomarkers along the entire length of the
esophagus, thus maximizing epithelial and luminal interrogation.
Limitations of the study include the use of patient controls
with an endoscopically and histologically normal esophagus, and
that comparisons between subjects with active/inactive EoE were
cross-sectional rather than longitudinal in the same subject. Since
the study was not designed to track patients with respect to
treatments, this was not fully addressed and will be the focus of
future studies. Limitations of the 1-hour EST include that it
cannot be used in patients who are unable to swallow pills or in
those with esophageal narrowing or allergy to the gelatin capsule.
A potential confounding variable is that atopic patients may
swallow EAPs derived from nasal, pulmonary, or ocular secre-
tions; these secretions may adhere to the EST and increase the
EST EAP concentrations. We have not noted any correlation
between self-reported comorbid allergic disease and increased
levels of the EAPs in EST samples (6).
Results from the current study support use of the 1-hour EST
as a surrogate for quantifyingmucosal eosinophilic inflammation
in patients with a known or suspected diagnosis of EoE. Dual
quantitation of the EST-captured EAPs, Eot3 and MBP-1, can be
converted by nomogram or its underlying algorithm into an
“EoEScore” with multiple relevant uses including monitoring
disease activity and screening for undiagnosed EoE. Use of this
minimally invasive tool can improve the quality of patient’s lives,
reduce costs in clinical practice, and accelerate progress of ther-
apeutic trials.
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Table 4. Subject satisfaction survey
Question Pediatric subject Parent Adult subject
Willing to repeat EST?
Yes 45/46 (98%) 42/44 (95.5%) 11/12 (92%)
No 1/46 (2%) 2/44 (4.5%) 1/12 (8%)
No response 4 6 1
Prefer EST or endoscopy if subject needed
another evaluation?
EST 32/43 (74.4%) 32/43 (74.4%) 9/12 (75%)
Endoscopy 7/43 (16.3%) 5/43 (11.6%) 3/12 (25%)
Neither 4/43 (9.3%) 6/43 (14%) 0/12 (0%)
No response 7 7 1
Prefer EST or endoscopy if EST could provide
similar information?
EST 39/45 (87%) 41/43 (95%) 12/13 (92%)
Endoscopy 5/45 (11%) 0/43 (0%) 1/13 (8%)
Neither 1/45 (2%) 2/43 (5%) 0 (0%)
No response 5 7 0
EST, esophageal string test.
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